ArticleJAMA network open2026
A 10-Year Cost-Effectiveness Analysis of Metabolic and Bariatric Surgery in Adolescents.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in metabolic and bariatric surgery among adolescents, 2016-2025.Journal of pediatric surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Obesity affects 1 in 5 US children, with the global prevalence projected to double by 2035. Among adolescents with severe obesity, metabolic and bariatric surgery (MBS) yields durable weight loss and comorbidity improvement, although its long-term cost-effectiveness remains uncertain. Objective: To evaluate the 10-year cost-effectiveness of MBS for adolescents with severe obesity using recently published results from the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. Design, Setting, and Participants: This economic evaluation used a microsimulation model of a cohort of 100 000 simulated adolescents in the US health care sector to project health and cost outcomes of no surgery, Roux-en-Y gastric bypass (RYGB), and sleeve gastrectomy over 10 years among adolescents with severe obesity. Model inputs, including longitudinal clinical performance, were derived from Teen-LABS study data, published literature, and national databases. Data were analyzed from April 2023 to October 2025. Main Outcomes and Measures: Quality-adjusted life-years (QALYs), costs (2022 US dollars), and incremental cost-effectiveness ratios (ICERs), with future costs and QALYs discounted at 3.0% annually. A willingness-to-pay (WTP) threshold of $100 000 per QALY gained was used to assess cost-effectiveness. Results: The population was a hypothetical cohort of 100 000 adolescents with the following baseline characteristics: age 17 years, body mass index 52.1, 75.0% female, 13.3% with type 2 diabetes, 4.9% with low ferritin, 37.2% with low vitamin D, and 0.4% with low vitamin B12. At 10 years, sleeve gastrectomy was projected to be the cost-effective strategy, with an ICER of $41 164 per QALY gained when compared with no surgery. RYGB yielded the most QALYs, although with a less favorable ICER of $557 751 per QALY gained compared with sleeve gastrectomy. However, in a direct comparison with no surgery, RYGB was estimated to be cost-effective, with an ICER of $50 271 per QALY gained. In sensitivity analyses, sleeve gastrectomy was consistently the cost-effective strategy. Conclusions and Relevance: In this economic evaluation of bariatric surgery for adolescents with severe obesity, both RYGB and sleeve gastrectomy were determined to be cost-effective when compared with no surgery. However, sleeve gastrectomy was estimated to be the cost-effective strategy over a 10-year time horizon when simultaneously comparing all 3 interventions. These findings complement established clinical evidence of the long-term benefits of MBS, supporting its economic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.